spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  calcium channel blocker 

 HSMN NewsFeed - 17 Oct 2022
Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 17 May 2021
Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 25 Sep 2019
Katerzia(TM), the First and Only Amlodipine Oral Suspension, 1 mg/mL, is Now Commercially Available for Pediatric Patients 6 Years of Age and Older
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 10 Sep 2019
Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 1 Aug 2017
Milestone Pharmaceuticals Closes $55 Million Series C Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 6 Jun 2016
Allergan Announces FDA Approval of BYVALSON(TM) (nebivolol and valsartan)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 29 Jan 2016
Viacoram(R) now approved in Canada as a new first line treatment in hypertension
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 18 Dec 2014
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 16 Dec 2014
Novartis gains FDA approval for Signifor(R) LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2013
Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 4 Jun 2013
Edge Therapeutics Raises $18 Million to Advance Clinical Development of Potentially Life-Saving Hospital Products
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Aug 2012
Edge Therapeutics Appoints Drug-Delivery Luminary Dr. Robert Langer to Chair Scientific Advisory Committee
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2010
Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2010
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic(R)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 19 Oct 2009
FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and Twynsta(R) as New Combination Treatment for High Blood Pressure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 17 Jun 2009
Neuromed Announces Sale of U.S. Rights to Drug Candidate Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) to Mallinckrodt
Biopharmaceuticals
 HSMN NewsFeed - 18 May 2009
AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
Biopharmaceuticals
 HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2009
New Data Shows AZOR(R) (Amlodipine and Olmesartan Medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Mar 2009
Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Biopharmaceuticals Pain Management
 HSMN NewsFeed - 11 Mar 2009
St. Jude Medical Announces European CE Mark Approval of Neurostimulation System for Chronic Angina
Devices Neurology Cardiology Regulatory
 HSMN NewsFeed - 28 Jan 2009
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2009
Hydra Biosciences Raises $22 Million in Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Nov 2008
FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 26 Aug 2008
New Publication Shows Cleviprex(TM) is Safe and Effective for Treatment of Acute, Severe Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 4 Aug 2008
The Medicines Company's Cleviprex(TM) Receives FDA Approval
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Aug 2008
EKR Therapeutics Receives Approval for Ready-to-Use Intravenous Bags of Cardene(R) I.V.
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 May 2008
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
Biopharmaceuticals
 HSMN NewsFeed - 1 May 2008
Coversyl(R) Protects Hypertensive Patients Against New-Onset Diabetes
Biopharmaceuticals
 HSMN NewsFeed - 29 Apr 2008
Neuromed Names Sean Cunliffe Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2008
Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Mar 2008
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 19 Mar 2008
Forest Laboratories Announces Resignation of Ivan Gergel, MD
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2008
EKR Therapeutics and PDL BioPharma Sign Asset Purchase Agreement for Cardiovascular Products
Biopharmaceuticals Acquisitions Cardiology
 HSMN NewsFeed - 22 Jan 2008
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Jan 2008
Recordati Licenses Kentera(R) From Watson Pharmaceuticals Inc. (U.S.A.) for Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 Dec 2007
Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Nov 2007
Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 27 Nov 2007
Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Oct 2007
Polyanalgesic Consensus Panel's New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain
Biopharmaceuticals
 HSMN NewsFeed - 15 Oct 2007
Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
Biopharmaceuticals Pain Mangement FDA
 HSMN NewsFeed - 1 Oct 2007
Recordati Acquires Orphan Europe, a European Group Specialized in Rare Diseases
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Sep 2007
AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Aug 2007
Neuromed Raises US$53.3 Million in Series E Financing to Accelerate Development of Pain Treatments
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Biopharmaceuticals
 HSMN NewsFeed - 8 Aug 2007
Neuromed Announces that Merck & Co., Inc. Discontinues Development of Pain Drug Candidate, Joint Research Program Continues
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2007
Neuromed Appoints Mario Orlando as Vice President of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jul 2007
Lupin Receives Final Approval for Amlodipine Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 21 Jun 2007
Exforge(R) Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jun 2007
CardioDynamics Announces New ICG Hypertension Evidence
Devices Monitoring Cardiology
 HSMN NewsFeed - 11 Jun 2007
US Court Allows Teva to Resume US Sales of Its Generic Version of Lotrel
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 21 May 2007
Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Apr 2007
Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Nimotop(R)
Biopharmaceuticals Cardiology Generics
 HSMN NewsFeed - 24 Apr 2007
Neuromed Licenses Phase 3 Chronic Pain Product from ALZA Corporation
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 27 Mar 2007
United Therapeutics and Mochida Pharmaceutical Sign Remodulin Distribution Agreement for Japan
Biopharmaceuticals Distribution
 HSMN NewsFeed - 27 Mar 2007
Pivotal Phase III Findings With Investigational Drug Cleviprex(TM) (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Mar 2007
Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Feb 2007
Dr. David D. Waters Joins Anthera Pharmaceuticals as Cardiovascular Research Fellow
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2007
The Medicines Company's Cleviprex(TM) (Clevidipine) Phase III Safety Trials Meet Pre-Specified Objectives
Biopharmaceuticals
 HSMN NewsFeed - 22 Dec 2006
Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients with High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2006
Risk of Heart Attack Significantly Reduced in About 90 days by Modern Combination of Drugs
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 Nov 2006
Par Pharmaceutical Begins Shipment of Generic TOPROL-XL(R)
Biopharmaceuticals Generics Distribution
 HSMN NewsFeed - 9 Oct 2006
Cardax Pharmaceuticals Appoints Fred Pashkow, MD, as EVP/CMO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Sep 2006
KV Pharmaceutical Company Receives ANDA Approval From U.S. FDA for Six Strengths of Diltiazem HCl ER Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 11 Sep 2006
The Medicines Company Completes Clevidipine Phase III Safety Trials and Initiates Phase III Severe Hypertension Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Sep 2006
Amlodipine Based Regimen to Lower Blood Pressure, Reduces the Risk of New-Onset Diabetes in Hypertensive Patients by More Than a Third
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Jun 2006
FDA Approves New Lotrel(R) 5/40 mg and 10/40 mg Dosage Strengths
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 May 2006
Angina Patients Cost Managed Care Over Twice as Much as Coronary Artery Disease Patients Without Angina
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Apr 2006
US Submission of Exforge(R) Accepted for Review by the FDA as a New Therapy Option for High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Apr 2006
New Drug Application (NDA) for Rasilez(R) (Aliskiren), an Innovative Oral Renin Inhibitor to Treat High Blood Pressure, Accepted for Review by the US FDA
Biopharmaceuticals
 HSMN NewsFeed - 22 Mar 2006
Study Shows LEVITRA(R) Treats Erectile Dysfunction Effectively in Men Taking Medications to Lower High Blood Pressure
Biopharmaceuticals
 HSMN NewsFeed - 19 Jan 2006
Novartis New Phase III Data With SPP100 (aliskiren, Rasilez) Reconfirms Strong Efficacy and Excellent Safety Profile as Monotherapy and Co-Administration Therapy for Treatment of Hypertension
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 56

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 56 additional stories matching:
calcium channel blocker
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.